Leap Therapeutics Transforms into Cypherpunk Technologies
Leap Therapeutics has transformed into Cypherpunk Technologies Inc., focusing on antibody therapies for cancer and digital assets. In its Q3 earnings report, the company reported a net loss of $3.3 million, with reduced operating expenses. It raised approximately $58.9 million through a private placement to support its new digital asset strategy, particularly Zcash. Despite the capital raise, Cypherpunk Technologies faces challenges in achieving profitability while balancing its biopharmaceutical and digital asset operations.
Leap Therapeutics ( (LPTX) ) has released its Q3 earnings. Here is a breakdown of the information Leap Therapeutics presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Leap Therapeutics, now known as Cypherpunk Technologies Inc., is a biopharmaceutical company focused on developing antibody therapies for cancer treatment, with a recent strategic shift towards digital assets. The company recently reported its earnings for the quarter ending September 30, 2025, highlighting a significant name change and strategic pivot. Key financial metrics indicate a net loss of $3.3 million for the quarter, with operating expenses substantially reduced from the previous year. The company also completed a private placement, raising approximately $58.9 million to support its new focus on digital assets, specifically Zcash. Looking forward, Cypherpunk Technologies aims to leverage its recent capital raise to support both its ongoing biopharmaceutical operations and its new digital asset strategy, although it continues to face challenges in achieving profitability.
